Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Non-Current Assets (2016 - 2025)

Regenxbio (RGNX) has 12 years of Non-Current Assets data on record, last reported at $171.8 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 8.64% year-over-year to $171.8 million; the TTM value through Dec 2025 reached $750.0 million, down 11.79%, while the annual FY2025 figure was $171.8 million, 8.64% down from the prior year.
  • Non-Current Assets reached $171.8 million in Q4 2025 per RGNX's latest filing, down from $193.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $595.1 million in Q4 2021 and bottomed at $171.8 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $323.3 million, with a median of $285.8 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: surged 236.26% in 2021, then crashed 42.73% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $595.1 million in 2021, then dropped by 29.88% to $417.3 million in 2022, then crashed by 42.73% to $239.0 million in 2023, then dropped by 21.34% to $188.0 million in 2024, then decreased by 8.64% to $171.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $171.8 million in Q4 2025, $193.2 million in Q3 2025, and $207.3 million in Q2 2025.